Contemporary guidelines have lowered the threshold for statin use in primary prevention (7.5% risk of a cardiovascular event over 10 years in the USA,1 10% risk according to National Institute for Health and Care Excellence [NICE] guidelines in the UK).2 Applying these thresholds, the majority of men over 50 years and more than half of women over 60 years will qualify for statin use. Countering the more widespread uptake of statin use in primary prevention advocated by these guidelines are claims, popularised by the lay press and uncritically published in some medical journals,3,4 that statin use is accompanied by an unacceptable incidence of side effects that adversely compromise lifestyle and which challenge whether the small absolute benefits in some lower risk groups are worth the intolerance of the statin.
Statins and myalgia: fact or fiction?
October 2015Br J Cardiol 2015;22:127–9doi:10.5837/bjc.2015.033 1 CommentClick any image to enlarge
First published online 21 October 2015
You can access this article without logging in.But don't miss out on the many Benefits of our Membership. Register Now.Already a member? Login Now.